KNTE vs. NGM, PRQR, ASMB, VTVT, BYSI, AVRO, IMMP, BLRX, SABS, and MACK
Should you be buying Kinnate Biopharma stock or one of its competitors? The main competitors of Kinnate Biopharma include NGM Biopharmaceuticals (NGM), ProQR Therapeutics (PRQR), Assembly Biosciences (ASMB), vTv Therapeutics (VTVT), BeyondSpring (BYSI), AVROBIO (AVRO), Immutep (IMMP), BioLineRx (BLRX), SAB Biotherapeutics (SABS), and Merrimack Pharmaceuticals (MACK). These companies are all part of the "biotechnology" industry.
Kinnate Biopharma (NASDAQ:KNTE) and NGM Biopharmaceuticals (NASDAQ:NGM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, community ranking, media sentiment and analyst recommendations.
NGM Biopharmaceuticals received 18 more outperform votes than Kinnate Biopharma when rated by MarketBeat users. Likewise, 60.38% of users gave NGM Biopharmaceuticals an outperform vote while only 40.00% of users gave Kinnate Biopharma an outperform vote.
80.9% of Kinnate Biopharma shares are owned by institutional investors. Comparatively, 75.7% of NGM Biopharmaceuticals shares are owned by institutional investors. 41.7% of Kinnate Biopharma shares are owned by company insiders. Comparatively, 35.9% of NGM Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, NGM Biopharmaceuticals had 1 more articles in the media than Kinnate Biopharma. MarketBeat recorded 1 mentions for NGM Biopharmaceuticals and 0 mentions for Kinnate Biopharma. Kinnate Biopharma's average media sentiment score of 0.00 equaled NGM Biopharmaceuticals'average media sentiment score.
Kinnate Biopharma has higher earnings, but lower revenue than NGM Biopharmaceuticals. Kinnate Biopharma is trading at a lower price-to-earnings ratio than NGM Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Kinnate Biopharma currently has a consensus target price of $11.72, suggesting a potential upside of 342.19%. NGM Biopharmaceuticals has a consensus target price of $3.68, suggesting a potential upside of 139.18%. Given Kinnate Biopharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Kinnate Biopharma is more favorable than NGM Biopharmaceuticals.
Kinnate Biopharma has a net margin of 0.00% compared to NGM Biopharmaceuticals' net margin of -3,223.34%. Kinnate Biopharma's return on equity of -62.31% beat NGM Biopharmaceuticals' return on equity.
Kinnate Biopharma has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, NGM Biopharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.
Summary
Kinnate Biopharma beats NGM Biopharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Kinnate Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for KNTE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KNTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kinnate Biopharma Competitors List
Related Companies and Tools
